Abstract
This study was designed to evaluate the safety and efficacy of adding oxaliplatin to preoperative chemoradiotherapy (CRT) with S-1 in patients with locally advanced rectal carcinoma (LARC). This was a multicenter phase II study in patients with histologically proven clinical stage T3 or T4 (any N, M0) LARC. Patients preoperatively received oral S-1 (80 mg/m(2)/day on days 1-5, 8-12, 22-27, and 29-33) and infusional oxaliplatin (60 mg/m(2) days on 1, 8, 22, and 29) plus radiotherapy (50.4 Gy), with a chemotherapy gap in the third week of radiotherapy. Pathological complete response (pCR) was the primary endpoint. Secondary endpoints included toxicity, compliance, R0 resection rate, and downstaging rate. A total of 45 patients were enrolled at six centers in Japan. All 45 patients received CRT, and 44 underwent operation. A pCR was achieved in 12 (27.3%) of the 44 patients who underwent surgery. Near-total tumor regression was confirmed in 47.7%. There were no grade 4 adverse events, and 11.1% of the patients had grade 3 adverse events. R0 resection was achieved in 95.5% of the patients. Preoperative CRT with S-1 plus oxaliplatin had a high pCR rate and a favorable toxicity profile.
References
Jul 1, 1996·Anti-cancer Drugs·T ShirasakaM Fukushima
Sep 15, 2006·The New England Journal of Medicine·Jean-François BossetUNKNOWN EORTC Radiotherapy Group Trial 22921
Sep 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Pierre GérardLaurent Bedenne
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jim CassidyLeonard Saltz
May 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel G HallerChris Twelves
Aug 10, 2010·The Lancet Oncology·Monique MaasGeerard L Beets
Sep 30, 2010·Oncology Reports·Masakazu FukushimaYu Sakata
Dec 15, 2010·Cancer Science·Benjamin ChuahLee S Rosen
May 25, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carlo AscheleLuca Boni
Dec 14, 2011·Oncology·Sotaro SadahiroYuko Nakayama
May 26, 2012·The Lancet Oncology·Claus RödelUNKNOWN German Rectal Cancer Study Group
Oct 31, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean-Pierre GérardThierry Conroy
Nov 15, 2013·The Lancet Oncology·Yasuhide YamadaKenichi Sugihara
Sep 3, 2014·PloS One·Meng SuChang-Lin Zou
Jan 24, 2015·Radiation Oncology·Soichiro IshiharaToshiaki Watanabe
Citations
Jul 5, 2019·Acta Oncologica·Bruce D Minsky
Mar 19, 2019·Oncology Letters·Hiroyuki FujikawaMasato Kusunoki
Jul 10, 2019·Molecular and Clinical Oncology·Takeshi NishikawaSoichiro Ishihara
Sep 25, 2017·Radiation Oncology·Hideomi YamashitaKeiichi Nakagawa
May 25, 2018·Journal of the Anus, Rectum and Colon·Naohito BeppuNaohiro Tomita
May 25, 2018·Journal of the Anus, Rectum and Colon·Kazushige KawaiToshiaki Watanabe
Dec 21, 2020·Journal of Radiation Research·Nobuki ImanoYasushi Nagata
Jan 25, 2021·International Journal of Clinical Oncology·Jun HigashijimaMitsuo Shimada
Feb 3, 2021·International Journal of Colorectal Disease·Hajime MorohashiKenichi Hakamada
Apr 22, 2019·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Keisaku KondoToshifusa Nakajima